Back to School: How biopharma can reboot drug development. Access exclusive analysis here
BCRX said peramivir failed to significantly reduce median time to alleviation of symptoms vs. placebo, the primary
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury